Ligand id: 7396

Name: siltuximab

No information available.
Summary of Clinical Use
Approved to treat multicentric Castleman’s disease (MCD), a rare blood disorder.
Mechanism Of Action and Pharmacodynamic Effects
Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of multicentric Castleman’s disease (MCD) [3]. Siltuximab is an anti-IL-6 monoclonal antibody which ameliorates the IL-6-induced increase in immunoglobulin-producing cells and production of acute phase proteins associated with MCD [2].
External links